CAMBRIDGE, Mass., July 11 /PRNewswire/ -- Cytel Inc., a leading provider of clinical trial design software and services, is pleased to announce that Dr. Jerald S. Schindler has joined the company as President of its Pharmaceutical Research Division.
Dr. Schindler comes to Cytel from Wyeth Research, where he served as Chief Biostatistician and Global Head of Biostatistics and Clinical Technology. During his time at Wyeth, Dr. Schindler was responsible for integrating several separate Biostatistics groups within Wyeth into one efficient, innovative global Biostatistics group. This Biostatistics group was responsible for designing and analyzing hundreds of clinical trials to evaluate the safety and efficacy of all new Wyeth drugs and biopharmaceuticals. These trials led to the regulatory approval of many new Wyeth products in the United States and around the world. He designed and implemented an integrated eClinical Information System that was selected by Bio-IT World as Best Platform in 2003. In addition, he has cultivated Wyeth’s partnership with the Harvard School of Public Health over the past 10 years. Dr. Schindler has served on the industry advisory board for the Clinical Data Interchange Standards Consortium (CDISC), and has jointly led a working group at PhRMA for developing an industry perspective on Adaptive Clinical trials.
“At Cytel, Dr. Schindler will be responsible for managing our interactive work with our clients in the pharmaceutical, biotechnology, and devices industries, aimed at helping them re-engineer the clinical research process,” said Dr. Ranganath Nayak, Cytel’s Chief Executive Officer. He added, “Our Pharmaceutical Research Division collaborates with our clients in their research efforts by helping to design and implement innovative approaches to clinical trials. These drastically reduce waste and improve time to market for successful drugs and devices. We are very happy, indeed, to welcome Jerry to Cytel. He is both a visionary and a very practical person, one who uniquely combines a knowledge of biostatistics and of technology with a senior manager’s business perspective.”
“I am delighted to be joining Cytel,” said Jerald Schindler. “I have used their products for many years, and I know that they create first-class statistical software. Now, Cytel will combine statistical consulting, interim data monitoring, and decision support along with their software. This presents a great opportunity for Cytel to partner with pharmaceutical companies to help optimize the clinical development process. Cytel has already begun to help companies design and analyze flexible, adaptive trials. I am particularly attracted to the strong ties Cytel has to leading academic researchers. These researchers will help us to maintain our innovative statistical methodology and also reinforce our integrity and independence as we work with clients on highly sensitive issues, such as monitoring unblinded clinical trial data, where these qualities will be much in demand,” he said.
About Cytel Inc.
Cytel Inc. has an 18-year track record as the premier provider of software and services for the design and analysis of clinical trials. Cytel provides software, training, and consulting to clinical trial sponsors seeking to run their trials more efficiently. Cytel’s East software is used by every division of the FDA and by hundreds of biostatisticians and clinicians in industry and academia to design, simulate and monitor group sequential and adaptive flexible clinical trials. More than 10,000 customers also use Cytel’s award- winning StatXact(R) and LogXact(R) software for exact statistical inference. Cytel Inc. is a privately owned company, headquartered in Cambridge, Massachusetts, and with software development operations in Pune, India. Major investors in Cytel include its founders and Merck Capital ventures.
Contact info: Michael Weitz Marketing & Communication Cytel Inc. mike@cytel.com 617.528.7132
Cytel Inc.
CONTACT: Michael Weitz, Marketing & Communication of Cytel Inc.,+1-617-528-7132, mike@cytel.com
Web site: http://www.cytel.com//
